Baird Said Trius Therapeutics (TSRX) Equity Offering News Provides Attractive Entry Point

Baird reiterated their Outperform rating and $13 price target on Trius Therapeutics (NASDAQ: TSRX) following the pricing of an 8.6 million share equity offering at $5.25.

"This was widely anticipated, and we understand and agree with management's decision to just bite the bullet here," the firm commented.

Fundamentals remain strong with the opportunity for significant value creation over a multi-year period, they said. With the financing overhang now removed, they see this as a "very attractive entry point."

For an analyst ratings summary and ratings history on Trius Therapeutics click here. For more ratings news on Trius Therapeutics click here.

Shares of Trius Therapeutics closed at $5.79 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Seaport Global Securities Starts ADI Global Distribution (ADIG) at Buy
• Yeti Holdings Inc. (YETI) PT Raised to $45 at Stifel on Beat and Raise Q2 Results
• Evercore ISI Starts Alvotech SA (ALVO) at Outperform